Guggenheim began coverage on shares of bluebird bio (NASDAQ:BLUE) in a research report sent to investors on Monday, The Fly reports. The brokerage issued a neutral rating on the biotechnology company’s stock.

Other equities analysts have also recently issued reports about the stock. Piper Jaffray Companies reaffirmed a buy rating on shares of bluebird bio in a research note on Thursday, August 2nd. Cowen reaffirmed a buy rating on shares of bluebird bio in a research note on Monday, June 4th. Gabelli started coverage on shares of bluebird bio in a research note on Thursday, July 12th. They set a buy rating and a $239.00 price target for the company. BMO Capital Markets reaffirmed a buy rating and set a $208.00 price target on shares of bluebird bio in a research note on Friday, August 3rd. Finally, SunTrust Banks reaffirmed a buy rating and set a $223.00 price target on shares of bluebird bio in a research note on Friday, August 3rd. Three equities research analysts have rated the stock with a sell rating, ten have assigned a hold rating and fifteen have assigned a buy rating to the company. The stock presently has a consensus rating of Hold and an average price target of $212.05.

NASDAQ BLUE opened at $137.20 on Monday. bluebird bio has a 52-week low of $119.90 and a 52-week high of $236.17.

bluebird bio (NASDAQ:BLUE) last posted its earnings results on Thursday, August 2nd. The biotechnology company reported ($2.91) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($2.30) by ($0.61). bluebird bio had a negative return on equity of 31.57% and a negative net margin of 1,281.01%. The business had revenue of $7.80 million for the quarter, compared to the consensus estimate of $10.68 million. During the same period in the previous year, the company posted ($1.73) earnings per share. bluebird bio’s revenue for the quarter was down 53.3% compared to the same quarter last year. equities research analysts anticipate that bluebird bio will post -10.8 earnings per share for the current fiscal year.

In related news, insider David Davidson sold 3,000 shares of the firm’s stock in a transaction on Wednesday, July 11th. The shares were sold at an average price of $180.15, for a total value of $540,450.00. Following the completion of the transaction, the insider now directly owns 27,905 shares of the company’s stock, valued at $5,027,085.75. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Alison Cecily Finger sold 259 shares of the firm’s stock in a transaction on Monday, August 20th. The shares were sold at an average price of $158.07, for a total transaction of $40,940.13. The disclosure for this sale can be found here. Insiders sold 72,685 shares of company stock valued at $11,829,905 over the last three months. 3.00% of the stock is owned by company insiders.

Several large investors have recently added to or reduced their stakes in the stock. FMR LLC grew its stake in shares of bluebird bio by 0.3% in the second quarter. FMR LLC now owns 7,517,890 shares of the biotechnology company’s stock valued at $1,179,933,000 after buying an additional 20,363 shares in the last quarter. BlackRock Inc. grew its stake in shares of bluebird bio by 1.0% in the first quarter. BlackRock Inc. now owns 3,868,157 shares of the biotechnology company’s stock valued at $660,489,000 after buying an additional 36,786 shares in the last quarter. OppenheimerFunds Inc. grew its stake in shares of bluebird bio by 3.0% in the second quarter. OppenheimerFunds Inc. now owns 794,126 shares of the biotechnology company’s stock valued at $124,638,000 after buying an additional 23,016 shares in the last quarter. Northern Trust Corp grew its stake in shares of bluebird bio by 0.4% in the first quarter. Northern Trust Corp now owns 592,198 shares of the biotechnology company’s stock valued at $101,118,000 after buying an additional 2,644 shares in the last quarter. Finally, Jennison Associates LLC grew its stake in shares of bluebird bio by 1.9% in the second quarter. Jennison Associates LLC now owns 512,740 shares of the biotechnology company’s stock valued at $80,475,000 after buying an additional 9,677 shares in the last quarter. 98.45% of the stock is owned by institutional investors and hedge funds.

About bluebird bio

bluebird bio, Inc, a clinical-stage biotechnology company, focuses on developing transformative gene therapies for severe genetic diseases and cancer. Its product candidates include Lenti-D that is in Phase II/III clinical trials for the treatment of cerebral adrenoleukodystrophy, a rare hereditary neurological disorder; and LentiGlobin, which is in various clinical studies for the treatment of transfusion- transfusion-dependent ß-thalassemia and severe sickle cell disease.

Featured Story: Hedge Funds Explained

The Fly

Analyst Recommendations for bluebird bio (NASDAQ:BLUE)

Receive News & Ratings for bluebird bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio and related companies with MarketBeat.com's FREE daily email newsletter.